Small molecule · Inhibitor of HBV reverse transcriptase · developed by Gilead Sciences
Tenofovir alafenamide is a lipophilic phosphonamidate prodrug of tenofovir, a nucleoside reverse transcriptase inhibitor. After hepatocyte uptake and conversion to tenofovir diphosphate, it is incorporated into viral DNA and terminates chain elongation, inhibiting hepatitis B virus replication. It is studied in chronic hepatitis B.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 14, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04891770 | Phase 2 | Chronic Hepatitis B | Completed | VIR |
| NCT04629976 | Phase 1 | Chronic Hepatitis B | Completed | LGND |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Hepatitis B
Updated Nov 1, 2026.